ozagrel
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Sep 26, 2010 (NCT01211951)
Timeline
Indications
Mechanism of action
- Thromboxane A2 receptorINHIBITOR
TBXA2R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- kct-0809
- kct-0809
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02503163 | Phase 3 | Jul 17, 2015 | Kissei Pharmaceuticals |
| NCT02503189 | Phase 3 | Jul 17, 2015 | Kissei Pharmaceuticals |
| NCT02503176 | Phase 3 | Jul 17, 2015 | Kissei Pharmaceuticals |
| NCT01890941 | Phase 2 | Jun 27, 2013 | Kissei Pharmaceuticals |
| NCT01692145 | Phase 2 | Sep 20, 2012 | Kissei Pharmaceuticals |
| NCT01427816 | Phase 2 | Sep 1, 2011 | Kissei Pharmaceuticals |
| NCT01211951 | Phase 2 | Sep 26, 2010 | Kissei Pharmaceuticals |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kissei Pharmaceuticals | For profit | 7 | 7 | 2 | 2010 |
1 organizations
Page 1 / 1